達力普控股(01921.HK)委任張霆邦為聯席公司祕書及授權代表
格隆匯9月10日丨達力普控股(01921.HK)宣佈,自2021年9月10日起,周卓言已辭任公司的聯席公司祕書;(ii)王千華不再擔任公司聯交所上市規則第3.05條項下的授權代表("授權代表")、香港法例第622章公司條例第16部項下在香港代表公司接受送達法律程序文件的授權代表("公司條例項下的授權代表")以及集團的財務及投資者關係總監。王千華留任聯席公司祕書;及(iii)具備上市規則第3.28及8.17條項下規定的必要資格及經驗的張霆邦已獲委任為聯席公司祕書、授權代表及公司條例項下的授權代表。張霆邦亦已獲委任為集團的財務及投資者關係總監。於上述變動後,聯席公司祕書為王千華及張霆邦。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.